drugset / Trial / NCT01265927
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Phase 1
Completed
10 enrolled
Indiana University
Breast Cancer Research Foundation · collabGeron Corporation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A study to evaluate safety and biologic effects of giving GRN163L in combination with trastuzumab in patients diagnosed with HER2+ metastatic breast cancer that is resistant to therapy with trastuzumab.
Timeline
- Start
- 2011-01
- Primary completion
- 2012-08
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imetelstat | Oligonucleotide (other) | — | Other |
| Background | Trastuzumab | Monoclonal antibody | — | Other |